From: cyberdost@mha.gov.in Subject: COVID-19 Vaccine Related cyber frauds
Sir/Madam,
Summary
COVID-19 vaccine is planned to be released in phased manner by Government. Fraudster
may use this opportunity to defraud people through various modes and means like providing priority/early access, fake apps, fake websites/SMS links etc.
Modus Operandi:
1. Fraudsters may call citizens or send SMS, impersonating as government authorized
distributors and ask them to submit documents/money for getting priority access to vaccine dose. 2. Fake Portals offering cashback/discounts, accepting online payments to book appointment or home delivery of vaccines may be created by fraudsters. 3. Fraudsters may also use dark web as a platform to sell fake remedies/vaccines or medicines. 4. Social media and search engine digital advertisement may also be created by fraudster to lure victims. 5. Miscreants may also spread fake videos/news pertaining to side effects of COVID-19 vaccine over social media or chat messengers to create social unrest.
Suggestions:
1. Avail Vaccine related facility/service/Information from official government website and
mobile apps. Typically government websites will have “.gov.in” domain. 2. Be vigilant if you get calls from unknown callers promising early vaccine access or delivery. Never perform any financial transaction upon request by unknown caller as it may be an attempt to get your personal details or to defraud you. 3. Avoid clicking on links of website sent through SMS or install apps related to COVID- 19 vaccine. 4. Thumbnails in digital advertisement on OTT platforms and social media may be misleading. Check for the publisher/source of digital advertisement mentioned at the bottom of thumbnail. 5. Verify the genuineness source of news/post related to COVID-19 vaccine harmful effects.
Regards
Threat Analytical Unit (TAU)
Indian Cyber Crime Coordination Centre CIS Division, MHA 011-23093697 This report is provided "as is" for informational purposes only. The (Indian Cyber Crime Coordination Centre) does not provide any warranties of any kind regarding any information contained herein. The I4C does not endorse any commercial product or service referenced in this newsletter/Advisory or otherwise.